Axogen announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap. The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale. Additional data analysis found that over the 12-month course of follow-up, the Axoguard Nerve Cap group demonstrated statistical superiority for reduction in the total pain reported by participants compared to the standard-of-care neurectomy group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXGN:
- Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
- AxoGen raises 2023 revenue view to upper end of $154M-$159M view
- AxoGen sees Q4 revenue $42.7M, consensus $40.68M
- Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
- AxoGen CEO Karen Zaderej to retire from company by January 2025